Перейти к главному меню навигации Перейти к основному контенту Перейти к нижнему колонтитулу сайта

СИНДРОМ ОТМЕНЫ ПРИЕМА АНТИДЕПРЕССАНТОВ (АЛГОРИТМ ПРОФИЛАКТИКИ И КОРРЕКЦИИ)

Аннотация

Антидепрессанты (АД) являются одним из наиболее часто используемых классов лекарственных препаратов (ЛП), при этом частота их назначения и длительность приема ежегодно растут. В клинической практике врачи нередко сталкиваются с необходимостью отмены или замены АД вследствие недостаточной эффективности или плохой переносимости. Данная задача является непростой для практикующего врача, так как отмена или резкое снижение дозы АД может привести к появлению соматических и психических симптомов отмены различной степени тяжести и продолжительности от легких и кратковременных до тяжелых и длительных, приводящих к нарушению функционирования пациента и психосоциальным проблемам. В литературе этот феномен получил название синдрома отмены приема АД (СОПА). В обзорной статье изложены основные результаты клинических исследований, посвященных изучению СОПА, и   современные теоретические представления о данной проблеме. В эпидемиологической части обзора нами было проанализированы результаты 4 международных опросов, 137 онлайн постов, 2 систематических обзоров, 3 когортных исследований, 2 рандомизированных клинических исследований с общей численностью выборки более 9171 человек.  На основании чего было выявлено, что показатели заболеваемости СОПА колеблются в диапазоне от 27% до 86%; при этом 43% - 51% опрашиваемых отмечают, что симптомы отмены имеют тяжелую степень выраженности и могут продолжаться более 2 недель. В статье также рассмотрены вероятные нейробиологичские механизмы развития СОПА, даются практические рекомендации и алгоритм по профилактике и коррекции симптомов СОПА. 

Ключевые слова

антидепрессанты, синдром отмены, симптомы, диагностика, нейробиология

PDF

Библиографические ссылки

  1. Department of Health and Social Care (DHSC). Hansard: Prescriptions drugs – written question. – 128871. – 2018. – Available at: https://www.parliament.uk/business/ publications/written-questions-answers-statements/written-question/Commons/2018-02-21/128871/ (accessed May 3, 2023)
  2. Johnson C.F., Macdonald H.J., Atkinson P. et al. Reviewing long-term antidepressants can reduce drug burden: A prospective observational cohort study // The British Journal of General Practice: The Journal of the Royal College of General Practitioners. – 2012. – Vol. 62 (604). – Pp. e773–e779. – https://doi.org/10.3399/bjgp12X658304
  3. Pratt L., Brody D., Gu Q. Antidepressant use among persons aged 12 and over: United States, 2011–2014 // National Center for Health Statistics Data Brief data brief. – 2017. – Vol. 283 – Pp. 1–8.
  4. Mojtabai R., Olfson M. National trends in long-term use of antidepressant medications: results from the U.S. National Health and Nutrition Examination Survey // The Journal of Clinical Psychiatry. – 2014. – Vol. 75(2). – Pp. 169–177. – https://doi.org/10.4088/JCP.13m08443
  5. NHS Digital. Prescriptions dispensed in the community – Statistics for England, 2006– 2016. – 2017. – Available at: https://digital.nhs.uk/data-and-information/publications/ statistical/prescriptions-dispensed-in-the-community/prescriptions-dispensed-in-thecommunity-statistics-for-england-2006-2016-pas (accessed May 3, 2023).
  6. Worl population review. Country rankings. – Accessed by: https://worldpopulationreview. com/country-rankings/depression-rates-by-country (accessed May 3, 2023).
  7. В конце сентября в России в 2,2 раза выросли продажи антидепрессантов // Forbes. – Available at: https://www.forbes.ru/forbeslife/478991-v-konce-sentabra-v-rossii-v2-2-raza-vyrosli-prodazi-antidepressantov (accessed May 3, 2023)
  8. Cascade E.F., Kalali A.H., Thase M.E. Use of antidepressants: expansion beyond depression and anxiety // Psychiatry. – 2007. – Vol. 4 (12). – Pp. 25–28.
  9. Ambresin G., Palmer V., Densley K. et al. What factors influence long-term antidepressant use in primary care? Findings from the Australian diamond cohort study // Journal of affective disorders. – 2015. – Vol. 176. – Pp. 125–132. – https://doi.org/10.1016/j.jad.2015.01.055
  10. Fornaro M., Cattaneo C.I., De Berardis D. et al. Antidepressant discontinuation syndrome: A state-of-the-art clinical review // European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology. – 2023. – Vol. 66. – Pp. 1–10. – https://doi.org/10.1016/j.euroneuro.2022.10.005
  11. Papp A., Onton J.A. Brain Zaps: An Underappreciated Symptom of Antidepressant Discontinuation // Prim Care Companion CNS Disord. – 2018. – Vol. 20 (6). – P.18m02311.
  12. Warner C.H., Bobo W., Warner C. et al. Antidepressant discontinuation syndrome // American Family Physician. – 2006. – Vol. 74 (3). – Pp. 449–456.
  13. Healy D. Data based medicine paper: Dependence and withdrawal. – 2012. – Available at: http://davidhealy.org/wp-content/uploads/2012/06/DBM-Paper-DependenceandWithdrawal.pdf (accessed May 3, 2023).
  14. Goldstein T.R., Frye M.A., Denicoff K.D. et al. Antidepressant discontinuation-related mania: critical prospective observation and theoretical implications in bipolar disorder // The Journal of Clinical Psychiatry. – 1999. – Vol. 60 (8). – Pp. 563–569.
  15. Narayan V., Haddad P.M. Antidepressant discontinuation manic states: a critical review of the literature and suggested diagnostic criteria // Journal of Psychopharmacology (Oxford, England). – 2011. – Vol. 25 (3). – Pp. 306–313. – https://doi.org/10.1177/0269881109359094
  16. Holguín-Lew J.C., Bell V. “When I want to cry I can’t”: Inability to cry following SSRI treatment // Revista Colombiana de Psiquiatria. – 2013. – Vol. 42 (4). – Pp. 304–310. – https://doi.org/10.1016/S0034-7450(13)70026-X
  17. Csoka A.B., Shipko S. Persistent sexual side effects after SSRI discontinuation // Psychotherapy and Psychosomatics. – 2006. – Vol. 75 (3). – Pp. 187–188. – https://doi.org/10.1159/000091777
  18. Fava G.A., Benasi G., Lucente M. et al. Withdrawal symptoms after serotonin-noradrenaline reuptake inhibitor discontinuation: Systematic review // Psychotherapy and Psychosomatics. – 2018. – Vol. 87 (4). – Pp. 195–203. – https://doi.org/10.1159/000491524
  19. Diagnostic and Statistical Manual of mental disorders, fifth edition // APA. – 2013. – Available at: https://cdn.websiteeditor.net/30f11123991548a0af708722d458e476/ files/uploaded/DSM %2520V.pdf (accessed May 3, 2023).
  20. American psychiatric association practice guideline for the treatment of patients with major depressive disorder (3rd ed.) / APA. – 2010. – Available at: https://psychiatryonline. org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf (accessed March 15, 2023).
  21. Depression in adults: recognition and management. 1.1 и 1.9.2.1, CG90 / NICE. – 2009. – URL: https://www.nice.org.uk/guidance/cg90 (accessed March 18, 2023).
  22. Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults // NICE. – 2022. – Available at: https://www.ncbi.nlm.nih.gov/books/NBK580677/ (дата обращения 20.03.2023)
  23. Iacobucci G. NICE updates antidepressant guidelines to reflect severity and length of withdrawal symptoms // BMJ. – 2019. – Vol. 367. – Art. l6103. – https://doi.org/10.1136/bmj.l6103
  24. Mahase E. Antidepressant withdrawal guidance must be updated to reflect evidence // BMJ. – 2019. – Vol. 365. – Art. l2283. – https://doi.org/10.1136/bmj.l2283
  25. Davies J., Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based? // Addictive Behaviors. – 2019. – Vol. 97. – Pp. 111–121. – https://doi.org/10.1016/j.addbeh.2018.08.027
  26. Chouinard G., Chouinard V.A. New classification of selective serotonin reuptake inhibitor withdrawal // Psychotherapy and Psychosomatics. – 2015. – Vol. 84 (2). – Pp. 63–71. – https://doi.org/10.1159/000371865
  27. Cosci F., Chouinard G. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications // Psychotherapy and Psychosomatics. – 2020. – Vol. 89 (5). – Pp. 283–306. – https://doi.org/10.1159/000506868
  28. Royal College of Psychiatrists. Coming off antidepressants. – 2012. – Available at: http://www.rcpsych.ac.uk/healthadvice/treatmentswellbeing/antidepressants/comingoffantidepressants.aspx (accessed May 3, 2023).
  29. Read J., Cartwright C., Gibson K. Adverse emotional and interpersonal effects reported by 1829 New Zealanders while taking antidepressants // Psychiatry Research. – 2014. – Vol. 216 (1). – Pp. 67–73. – https://doi.org/10.1016/j.psychres.2014.01.042
  30. Read J., Williams J. Adverse effects of antidepressants reported by a large international cohort: Emotional blunting, suicidality, and withdrawal effects // Current Drug Safety. – 2018. – Vol. 13 (3). – Pp. 176–186. – https://doi.org/10.2174/1574886313666180605095130
  31. Cartwright C., Gibson K., Read J. et al. Long-term antidepressant use: patient perspectives of benefits and adverse effects // Patient Preference and Adherence. – 2016. – Vol. 10. – Pp. 1401–1407. – https://doi.org/10.2147/PPA.S110632
  32. Groot P.C., & Van Os, J. Antidepressant tapering strips to help people come off medication more safely // Psychosis. – 2018. – Vol. 10 (2). – Pp. 142–145
  33. Davies J., Pauli R., Montagu L. Antidepressant withdrawal: A survey of patients’ experience by the all-party parliamentary group for prescribed drug dependence. – 2018. – Available at: http://prescribeddrug.org/wp-content/uploads/2018/09/APPG-PDD-Antidepressant-Withdrawal-Patient-Survey.pdf (accessed May 3, 2023).
  34. Stockmann T., Odegbaro D., Timimi S. et al. SSRI and SNRI withdrawal symptoms reported on an internet forum // The International Journal of Risk & Safety in Medicine. – 2018. – https://doi.org/10.3233/JRS-180018
  35. Zajecka J., Fawcett J., Amsterdam J. et al. Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study // J Clin Psychopharmacol. – 1998. – Vol. 18 (3). – Pp. 193–197.
  36. Belaise C., Gatti A., Chouinard V.A. et al. Persistent postwithdrawal disorders induced by paroxetine, a selective serotonin reuptake inhibitor, and treated with specific cognitive behavioral therapy // Psychotherapy and Psychosomatics. – 2014. – Vol. 83 (4). – Pp. 247– 248. – https://doi.org/10.1159/000362317
  37. Fava G.A., Gatti A., Belaise C. et al. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: A systematic review // Psychotherapy and Psychosomatics. – 2015. – Vol. 84 (2). – Pp. 72–81. – https://doi.org/10.1159/000370338
  38. Stahl S.M. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects // Journal of Affective Disorders. – 1998. – Vol. 51 (3). – Pp. 215–235. – https://doi.org/10.1016/s0165-0327(98)00221-3
  39. Blier P., Tremblay P. Physiologic mechanisms underlying the antidepressant discontinuation syndrome // The Journal of Clinical Psychiatry. – 2006. – Vol. 67 (4). – Pp. 8–13.
  40. Szabo S.T., de Montigny C., Blier P. Modulation of noradrenergic neuronal firing by selective serotonin reuptake blockers // British Journal of Pharmacology. – 1999. – Vol. 126 (3). – Pp. 568–571. – https://doi.org/10.1038/sj.bjp.0702343
  41. Garner E.M., Kelly M.W., Thompson D.F. Tricyclic antidepressant withdrawal syndrome // The Annals of Pharmacotherapy. – 1993. – Vol. 27 (9). – Pp. 1068–1072. – https://doi.org/10.1177/106002809302700912
  42. Coupland N.J., Bell C.J., Potokar J.P. Serotonin reuptake inhibitor withdrawal // Journal of Clinical Psychopharmacology. – 1996. – Vol. 16 (5). – Pp. 356–362. – https://doi.org/10.1097/00004714-199610000-00003
  43. Meyer J.H., Wilson A.A., Sagrati S. et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C] DASB positron emission tomography study // The American Journal of Psychiatry. – 2004. – Pp. 826–835
  44. Harvey B.H., McEwen B.S., Stein D.J. Neurobiology of antidepressant withdrawal: implications for the longitudinal outcome of depression // Biological Psychiatry. – 2003. – Vol. 54 (10). – Pp. 1105–1117. – https://doi.org/10.1016/s0006-3223(03)00528-6
  45. Renoir T. Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: A review of the clinical evidence and the possible mechanisms involved // Frontiers in Pharmacology. – 2013. – Vol. 4. – Art. 45. – https://doi.org/10.3389/fphar.2013.00045
  46. Jha M.K., Rush A.J., Trivedi M.H. When discontinuing SSRI antidepressants is a challenge: Management tips // The American Journal of Psychiatry. – 2018. – Vol. 175 (12). – Pp. 1176–1184. – https://doi.org/10.1176/appi.ajp.2018.18060692
  47. Schatzberg A.F., Haddad P., Kaplan E.M. et al. Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. Discontinuation consensus panel // J Clin Psychiatry. – 1997. – Vol. 58 (7). – Pp. 23–27.
  48. Hung C.I., Wang S.J., Liu C.Y. et al. Comorbidities and factors related to discontinuation of pharmacotherapy among outpatients with major depressive disorder // Comprehensive Psychiatry. – 2011. – Vol. 52 (4). – Pp. 370–377. – https://doi.org/10.1016/j.comppsych.2010.08.005
  49. Roca A., Imaz M.L., Torres A. et al. Unplanned pregnancy and discontinuation of SSRIs in pregnant women with previously treated affective disorder // Journal of Affective Disorders. – 2013. – Vol. 150 (3). – Pp. 807–813. – https://doi.org/10.1016/j.jad.2013.02.040
  50. Harvey B.H., Slabbert F.N. New insights on the antidepressant discontinuation syndrome // Human Psychopharmacology. – 2014. – Vol. 29 (6). – Pp. 503–516. – https://doi.org/10.1002/hup.2429
  51. Tomlinson A., Boaden K., Cipriani A. Withdrawal, dependence and adverse events of antidepressants: lessons from patients and data // Evidence-Based Mental Health. – 2019. – Vol. 22 (4). – Pp. 137–138. – https://doi.org/10.1136/ebmental-2019-300121
  52. Haddad, P., Anderson, I. Recognising and managing antidepressant discontinuation symptoms // Advances in Psychiatric Treatment. – 2007. – Vol. 13 (6). – Pp. 447–457. – https://doi.org/10.1192/apt.bp.105.001966
  53. Frank E., Prien R.F., Jarrett R.B. et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence // Archives of general psychiatry. – 1991. – Vol. 48 (9). – Pp. 851–855. – https://doi.org/10.1001/archpsyc.1991.01810330075011
  54. Hengartner M.P., Schulthess L., Sorensen A. et al. Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum // Therapeutic Advances in Psychopharmacology. – 2020. – Vol. 10. – Art. 2045125320980573. – https://doi.org/10.1177/2045125320980573
  55. Петрова Н.Н. Биполярное аффективное расстройство. Новые возможности терапии // Современная терапия психических расстройств. – 2022. – № 1. – С. 45–55. – https://doi.org/10.21265/PSYPH.2022.60.1.005
  56. Федорова Е.Ю. Терапия депрессивной фазы при быстроциклическом течении биполярного расстройства (клиническое наблюдение) // Современная терапия психических расстройств. – 2021. – № 4. – С. 50–56 – https://doi.org/10.21265/PSYPH.2021.80.22.006
  57. Psych scene hub. – Available at: https://psychscenehub.com/psychinsights/diagnosisand-management-of-antidepressant-withdrawal-the-hyperbolic-curve-and-ssri-withdrawal-2/ (accessed May 3, 2023).
  58. Davies J., Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based? // Addictive Behaviors. – 2019. – Vol. 97. – Pp. 111–121. – https://doi.org/10.1016/j.addbeh.2018.08.027
  59. Psychscenehub. Diagnosi and management of antidepressant withdrawal. – Available at: https://psychscenehub.com/psychinsights/diagnosis-and-management-of-antidepressant-withdrawal-the-hyperbolic-curve-and-ssri-withdrawal-2/ (accessed May 3, 2023).
  60. Horowitz M.A., Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms // The Lancet. Psychiatry. – 2019. – Vol. 6 (6). – Pp. 538–546. – https://doi.org/10.1016/S2215-0366(19)30032-X
  61. Malhi G.S., Bell E., Bassett D. et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders // Australian & New Zealand Journal of Psychiatry. – 2021. – Vol. 55 (1). – Pp. 7–117. – https://doi.org/10.1177/0004867420979353
  62. Федеральное руководство по использованию лекарственных средств (формулярная система). – 8-е изд., перераб. и доп. / под ред. А.Г. Чучалина, Ю.Б. Белоусова, В.В. Яснецова. – М., 2007.
  63. British National Formulary (March issue) / British Medical Association & Royal Pharmaceutical Society of Great Britain. – BMJ Publishing Group & RPS Publishing, 2007.
  64. Keuthen N.J., Cyr P., Ricciardi J.A. et al. Medication withdrawal symptoms in obsessivecompulsive disorder patients treated with paroxetine // Journal of Clinical Psychopharmacology. – 1994. – Vol. 14 (3). – Pp. 206–207. – https://doi.org/10.1097/00004714-199406000-00010
  65. Benazzi F. Re: Selective serotonin reuptake inhibitor discontinuation syndrome: putative mechanisms and prevention strategies // Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie. – 1999. – Vol. 44 (1). – Pp. 95–96.
  66. Михеенкова Н.М., Рывкин П.В., Мосолов С.Н. Серотониновый синдром: клиника, патофизиология и терапия // Современная терапия психических расстройств. – 2022. – № 2. – С. 53–63. – https://doi.org/10.21265/PSYPH.2022.90.61.006
  67. Мосолов С.Н., Малин Д.И., Рывкин П.В., Сычев Д.А. Лекарственные взаимодействия препаратов, применяемых в психиатрической практике // Современная терапия психических расстройств. – 2019. – № S1. – С. 2–35. – https://doi.org/10.21265/PSYPH.2019.50.40828
  68. Fava G.A., Cosci F. Understanding and Managing Withdrawal Syndromes After Discontinuation of Antidepressant Drugs // The Journal of Clinical Psychiatry. – 2019. – Vol. 80 (6). – Art. 19com12794. – https://doi.org/10.4088/JCP.19com12794
  69. Zwiebel S.J., Viguera A.C. Discontinuing antidepressants: Pearls and pitfalls // Cleveland Clinic Journal of Medicine. – 2022. – Vol. 89 (1). – Pp. 18–26. – https://doi.org/10.3949/ccjm.89a.21020
  70. Федеральное руководство по использованию лекарственных средств (формулярная система). – Вып. IV / Под ред. А.Г. Чучалина. – М., 2003.
  71. Haddad P. The SSRI discontinuation syndrome // Journal of Psychopharmacology (Oxford, England). – 1998. – Vol. 12 (3). – Pp. 305–313. – https://doi.org/10.1177/026988119801200311
  72. Ogle N.R., Akkerman S.R. Guidance for the discontinuation or switching of antidepressant therapies in adults // Journal of Pharmacy Practice. – 2013. – Vol. 26 (4). – Pp. 389– 396. – https://doi.org/10.1177/0897190012467210
  73. Ястребов Д.В. Симптоматика, ассоциированная с прекращением приема антидепрессантов // Психиатрия и психофармакотерапия. – 2008. – № 10. – С. 51–60.
  74. Ястребов Д.В. Симптоматика, ассоциированная с прекращением приема антидепрессантов: механизмы развития, способы предотвращения и коррекции // Психиатрия и психофармакотерапия. – 2011. – Т. 13, № 3. – С. 14–20.
  75. British National Formulary. – 2011. – Available at: https://farabipharma.ir/wp-content/ uploads/2017/07/bnf_61.pdf (accessed May 3, 2023).
  76. Keks N., Hope J., Keogh, S. Switching and stopping antidepressants // Australian Prescriber. – Vol. 39 (3). – Pp. 76–83. – https://doi.org/10.18773/austprescr.2016.039

Скачивания

Данные скачивания пока недоступны.